<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04529551</url>
  </required_header>
  <id_info>
    <org_study_id>CSD1601</org_study_id>
    <nct_id>NCT04529551</nct_id>
  </id_info>
  <brief_title>CSD1601: A Study to Evaluate the Exposure to Tar and Nicotine From Two Cigarette Products That Contain a Menthol Capsule in the Filter</brief_title>
  <official_title>CSD1601: A Crossover Study to Evaluate the Exposure to Tar and Nicotine From Two Cigarette Products That Contain a Menthol Capsule in the Filter</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RAI Services Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RAI Services Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate exposure to tar and nicotine from two cigarette products that&#xD;
      contain a menthol capsule in the filter, and provide a basis for comparing mouth-level&#xD;
      exposure when smokers smoke the two cigarette products.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will be randomly assigned to the order in which they will smoke two study cigarette&#xD;
      products (including one comparator product and one test product). Subjects will smoke each&#xD;
      study product exclusively for approximately one week prior to a test visit, with a different&#xD;
      product smoked each week over a two-week period. Cigarette butts will be collected the day&#xD;
      prior to each test visit for determination of Yield-in-Use (YIU) tar and nicotine levels.&#xD;
      Blood samples will be collected at each test visit for determination of blood cotinine&#xD;
      levels. Subjects will provide responses to questions during each test visit to assess their&#xD;
      cigarette smoking and cigarette butt collection behavior during the preceding day.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 8, 2016</start_date>
  <completion_date type="Actual">May 2, 2016</completion_date>
  <primary_completion_date type="Actual">May 2, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Yield-in-use tar per cigarette</measure>
    <time_frame>2 weeks</time_frame>
    <description>To compare the per cigarette YIU tar per cigarette from smoking product 1601A with those from smoking product 1601B.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Yield-in-use nicotine per cigarette</measure>
    <time_frame>2 weeks</time_frame>
    <description>To compare the per cigarette YIU nicotine per cigarette from smoking product 1601A with those from smoking product 1601B.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">55</enrollment>
  <condition>Smoking</condition>
  <condition>Tobacco Smoking</condition>
  <condition>Tobacco Use</condition>
  <arm_group>
    <arm_group_label>1601A, 1601B product use order</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will use 1601A for 1 week and then 1601B for 1 week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1601B, 1601A product use order</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will use 1601B for 1 week and then 1601A for 1 week.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>1601A</intervention_name>
    <description>A filtered, king size cigarette with a menthol capsule in the filter.</description>
    <arm_group_label>1601A, 1601B product use order</arm_group_label>
    <arm_group_label>1601B, 1601A product use order</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>1601B</intervention_name>
    <description>A filtered, king size cigarette with a menthol capsule in the filter.</description>
    <arm_group_label>1601A, 1601B product use order</arm_group_label>
    <arm_group_label>1601B, 1601A product use order</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Able to read, understand, and willing to sign an Informed Consent Form (ICF) written&#xD;
             in English;&#xD;
&#xD;
          2. Generally healthy males and females, 21 years of age or older, at Screening-&#xD;
             Enrollment Visit;&#xD;
&#xD;
          3. Self-reports smoking at least seven cigarettes per day and inhaling the smoke;&#xD;
&#xD;
          4. Usual brand of cigarette is one of the brand styles specified;&#xD;
&#xD;
          5. Smoked usual brand for ≥ 3 months;&#xD;
&#xD;
          6. Subject does not intend to delay a decision to quit smoking to participate in the&#xD;
             study.&#xD;
&#xD;
          7. Agrees to exclusively smoke the study cigarettes and not smoke or use any other&#xD;
             tobacco or nicotine-containing products during the course of the study.&#xD;
&#xD;
          8. Able to read and comprehend English.&#xD;
&#xD;
          9. Able to safely perform the required study procedures, as determined by the&#xD;
             Investigator.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Self-reported history of heart disease, kidney disease, asthma or any other lung&#xD;
             disease, diabetes, liver disease, hypertension, or hypercholesterolemia.&#xD;
&#xD;
          2. At risk for heart disease, i.e., obesity (body mass index [BMI] ≥ 40 kg/m2), as&#xD;
             determined by the Investigator;&#xD;
&#xD;
          3. Females ≥ 35 years of age currently using systemic, estrogen-containing contraception,&#xD;
             or hormone replacement therapy;&#xD;
&#xD;
          4. Postponing a decision to quit smoking (defined as planning a quit attempt within 30&#xD;
             days of the Screening-Enrollment Visit) to participate in this study;&#xD;
&#xD;
          5. Use of any medication or substance that aids in smoking cessation, including but not&#xD;
             limited to any nicotine-replacement therapy (NRT) (e.g., nicotine gum, lozenge,&#xD;
             patch), varenicline (Chantix®), bupropion (Wellbutrin®, Zyban®), or lobelia extract&#xD;
             within 30 days prior to the Screening-Enrollment Visit;&#xD;
&#xD;
          6. Females who test positive for pregnancy, are pregnant or breastfeeding, or plan to&#xD;
             become pregnant during the course of the study;&#xD;
&#xD;
          7. Determined by the Investigator to be inappropriate for the study;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan Austin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>High Point Clinical Trials Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>High Point Clinical Trials Center</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27265</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 24, 2020</study_first_submitted>
  <study_first_submitted_qc>August 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 27, 2020</study_first_posted>
  <last_update_submitted>August 24, 2020</last_update_submitted>
  <last_update_submitted_qc>August 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

